Atrion Corporation (Nasdaq:ATRI)
December 6th, 2018
Atrion Corporation fell $9.08 Thursday, down 1.16%, closing at $776.62. Despite the drop in price it hit a new 52 week high of $796.64.
ATRI was outperformed by the rest of the Healthcare sector which went down just 0.31%.
Expectations from 1 analyst points to the possibility that Atrion Corporation might drop somewhat (-62%), while Finbox has calculated (with low uncertainty) a fair value price of $456.42.
The market sectors were mixed Thursday with a majority of the sectors trending down. Real Estate saw the biggest increase of the day (2.67%), while Energy saw the biggest drop (1.77%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector dropping 13%.
Communication Services saw the biggest turnaround from its 5-day performance of -0.23%, as it went up 1.04%. Energy and Materials experienced turn arounds from their five day positive performance, Energy with a drop of 1.77%.
- Real Estate went up with a 2.67% change.
- Communication Services went up with a 1.04% change.
- Consumer Discretionary went up with a 0.61% change.
- Information Technology went up with a 0.23% change.
- Utilities went down with a -0.09% change.
- Consumer Staples went down with a -0.10% change.
- Healthcare went down with a -0.31% change.
- Industrials went down with a -0.55% change.
- Materials went down with a -1.38% change.
- Financials went down with a -1.44% change.
- Energy went down with a -1.77% change.
Atrion Corporation Info
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company’s cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers, as well as other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.